Ruoxi Hu Ph.D Overview

  • Primary Position
  • Chief Education...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 3

  • Med. Deal Size

  • Med. Valuation

Ruoxi Hu Ph.D General Information

Biography

Dr. Ruoxi Hu serves as Chief Education Officer at Manistee Therapeutics. He serves as an Investment Professional at Morningside Group. He served as a Senior Associate at Mass General Brigham Ventures. She served as a Senior Associate at Partners HealthCare Innovation. She serves as a Board Member at Mesentech, FireCyte Therapeutics, and Animated. She joined the Partners Innovation Fund in 2017. Previously, she was a Consultant at Clarion Healthcare, a boutique life sciences consulting firm. At Clarion, she worked with a range of clients from global pharmaceutical companies to emerging biotech on commercial strategy for preclinical/clinical-stage therapeutics in oncology, immunology, CNS, and rare diseases. She received her Ph.D. in Biological Sciences in Public Health from Harvard University, studying the role of microRNAs in asthma pathogenesis. She received her BSc Honors in Life Sciences from Queen's University in Canada.

Contact Information

Primary Position
Chief Education Officer, Manistee Therapeutics
Education
Harvard University, Ph.D. (Doctor of Philosophy)
Queen's University, BS (Bachelor of Science)
Gender
Female
Email
rh
Phone
+1 (857)
Address
  • 84 Barnes Hill Road
  • Concord, MA 01742
  • United States
+1 (617)

Ruoxi Hu Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
Manistee Therapeutics Company Chief Education Officer Concord, MA Other Healthcare Services
Morningside Group Investor Investment Professional Newton, MA Venture Capital

Ruoxi Hu Ph.D Board Seats (3)

Company Industry Ownership Status Financing Status Location Since
Apnimed Drug Discovery Privately Held (backing) Venture Capital-Backed Cambridge, MA
FireCyte Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Beverly, MA
Mesentech Drug Discovery Privately Held (backing) Venture Capital-Backed Vancouver, Canada

Ruoxi Hu Ph.D Lead Partner on Deals (2)

Ruoxi Hu Ph.D has been the lead partner on 2 deals. Their latest deal was with Mesentech, a drug discovery company. The deal was made for on 13-Apr-2022.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Mesentech 13-Apr-2022 Early Stage VC Completed Drug Discovery Vancouver, Canada
FireCyte Therapeutics 01-Feb-2022 Completed Drug Discovery Beverly, MA

Ruoxi Hu Ph.D Network (42)

Board Members (29)

Name Company Representing Location From
Jonathan Polak Mesentech Mesentech Vancouver, Canada
Shawnalea Frazier Ph.D FireCyte Therapeutics AbbVie Ventures Beverly, MA
FireCyte Therapeutics Self Beverly, MA
Mesentech Mesentech Vancouver, Canada
Mesentech Self Vancouver, Canada

Portfolio Executives (13)

Name Company Role Deal date Location
Anand Mehta Mesentech Chief Medical Officer 13-Apr-2022 Vancouver, Canada
Pieter Cullis Mesentech Co-Founder 13-Apr-2022 Vancouver, Canada
Mesentech Chief Executive Officer & Board Member 13-Apr-2022 Vancouver, Canada
Mesentech Chief Science Officer 13-Apr-2022 Vancouver, Canada
Mesentech Chief Development Officer 13-Apr-2022 Vancouver, Canada

Ruoxi Hu Ph.D FAQs

  • Who is Ruoxi Hu Ph.D?

    Dr. Ruoxi Hu serves as Chief Education Officer at Manistee Therapeutics.

  • How much does Ruoxi Hu Ph.D typically invest?

    Ruoxi Hu Ph.D's median deal size is .

  • What is Ruoxi Hu Ph.D’s main position?

    Ruoxi Hu Ph.D’s primary position is Chief Education Officer.

  • What are the contact details for Ruoxi Hu Ph.D?

    Ruoxi Hu Ph.D’s email address is rh and his phone number is +1 (857) .

  • How many active board seats does Ruoxi Hu Ph.D hold?

    Ruoxi Hu Ph.D holds 3 board seats including Apnimed, FireCyte Therapeutics, and Mesentech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »